# High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain Metastases

> **NCT06319950** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Taizhou Hospital** · enrollment: 255 (estimated)

## Conditions studied

- Lung Cancer, Nonsmall Cell

## Interventions

- **DRUG:** Furmonertinib
- **DRUG:** Osimertinib

## Key facts

- **NCT ID:** NCT06319950
- **Lead sponsor:** Taizhou Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-04-01
- **Primary completion:** 2026-12-30
- **Final completion:** 2026-12-30
- **Target enrollment:** 255 (ESTIMATED)
- **Last updated:** 2024-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06319950

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06319950, "High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain Metastases". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06319950. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*